- Home
- ZYME
ZYME
Zymeworks Inc.
as of 01-26-2026 3:55pm EST
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | MIDDLETOWN |
| Market Cap: | 2.0B | IPO Year: | 2017 |
| Target Price: | $32.75 | AVG Volume (30 days): | 900.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.84 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.03 - $28.49 | Next Earning Date: | 03-04-2026 |
| Revenue: | $134,481,000 | Revenue Growth: | 116.21% |
| Revenue Growth (this year): | 64.19% | Revenue Growth (next year): | 91.98% |
AI-Powered ZYME Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Zymeworks Inc. (ZYME)
EVP & Chief Medical Officer
Avg Cost/Share
$22.67
Shares
9,310
Total Value
$211,090.29
Owned After
26,708
SEC Form 4
Chief Scientific Officer
Avg Cost/Share
$22.67
Shares
9,560
Total Value
$216,758.66
Owned After
48,497
SEC Form 4
Chair & CEO
Avg Cost/Share
$22.67
Shares
30,424
Total Value
$689,818.56
Owned After
226,842
SEC Form 4
EVP & Chief Operating Officer
Avg Cost/Share
$22.67
Shares
6,120
Total Value
$138,761.82
Owned After
132,913
SEC Form 4
EVP & Chief Medical Officer
Avg Cost/Share
$25.10
Shares
10,538
Total Value
$264,471.13
Owned After
26,708
SEC Form 4
Chief Scientific Officer
Avg Cost/Share
$25.10
Shares
20,110
Total Value
$504,698.66
Owned After
48,497
Chair & CEO
Avg Cost/Share
$25.10
Shares
54,343
Total Value
$1,363,840.84
Owned After
226,842
Chair & CEO
Avg Cost/Share
$27.02
Shares
47,528
Total Value
$1,284,311.12
Owned After
226,842
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Smith Jeffrey T L | ZYME | EVP & Chief Medical Officer | Jan 12, 2026 | Sell | $22.67 | 9,310 | $211,090.29 | 26,708 | |
| Moore Paul Andrew | ZYME | Chief Scientific Officer | Jan 12, 2026 | Sell | $22.67 | 9,560 | $216,758.66 | 48,497 | |
| Galbraith Kenneth | ZYME | Chair & CEO | Jan 12, 2026 | Sell | $22.67 | 30,424 | $689,818.56 | 226,842 | |
| Hollywood Mark | ZYME | EVP & Chief Operating Officer | Jan 12, 2026 | Sell | $22.67 | 6,120 | $138,761.82 | 132,913 | |
| Smith Jeffrey T L | ZYME | EVP & Chief Medical Officer | Jan 5, 2026 | Sell | $25.10 | 10,538 | $264,471.13 | 26,708 | |
| Moore Paul Andrew | ZYME | Chief Scientific Officer | Jan 5, 2026 | Sell | $25.10 | 20,110 | $504,698.66 | 48,497 | |
| Galbraith Kenneth | ZYME | Chair & CEO | Jan 5, 2026 | Sell | $25.10 | 54,343 | $1,363,840.84 | 226,842 | |
| Galbraith Kenneth | ZYME | Chair & CEO | Dec 22, 2025 | Sell | $27.02 | 47,528 | $1,284,311.12 | 226,842 |
Compare ZYME vs Leading Stocks
See how ZYME stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ZYME Zymeworks Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.